Substituted indazoles of formula 1.0 that are kinase inhibitors
US7700601B2 · kind B2 · utility
38Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 28, 2007 |
| Grant date | Apr 20, 2010 |
| Priority date | — |
| Expiry date | Apr 25, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a compound of the formula:and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating protein kinase mediated diseases using the compound of formula 1.0. Also disclosed are methods of treating cancer using a compound of formula 1.0. The disclosed methods also include combination therapies wherein the compound of formula 1.0 is administered in combination with at least one addition pharmaceutically active ingredient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.